IRLAB Therapeutics AB (FRA:6IRA) Accounts Payable & Accrued Expense : €0.00 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is IRLAB Therapeutics AB Accounts Payable & Accrued Expense?

IRLAB Therapeutics AB's annual accounts payable & accrued expense declined from Dec. 2021 (€1.20 Mil) to Dec. 2022 (€0.91 Mil) but then increased from Dec. 2022 (€0.91 Mil) to Dec. 2023 (€0.94 Mil).

IRLAB Therapeutics AB Accounts Payable & Accrued Expense Historical Data

The historical data trend for IRLAB Therapeutics AB's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Accounts Payable & Accrued Expense Chart

IRLAB Therapeutics AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

0.81

0.36

1.20

0.91

0.94

IRLAB Therapeutics AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															-	0.94	-	-	-

IRLAB Therapeutics AB Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

IRLAB Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (FRA:6IRA) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

IRLAB A:Sweden

Address

Arvid Wallgren Backe 20, Goteborg, SWE, 413 46

Website

https://www.irlab.se

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines